Sponsrat Sponsrat

SynAct Pharma Board and Management extend lock-up period   UK Version

SynAct Pharma AB ("SynAct") today announced all members of its board and management team have extended the lock-up period for their SynAct Pharma shares until December 31, 2021. In total the lock-up agreements correspond to more than 20 percent of the votes and capital in SynAct Pharma.

Uppdaterad 2021-05-04
Publicerad 2021-05-04

“The members of the board and the entire management team have no intention of selling their shares now,” said Jeppe Øvlesen, CEO of SynAct Pharma. “We all see the incredible long-term potential our pipeline has and are committed to helping this company reach its potential.”

The information was submitted, through the agency of the contact person below, for publication on Mai 4, 2021.


Lås upp allt innehåll
Med Premium får du Sveriges bästa oberoende bevakning av finansbranschen

Logga in